Immuneering Corp (IMRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.82-4.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IMRX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | 0.0 | 0.3 | 2.1 | 2.3 |
| Total Revenues | — | — | — | 0.0 | 0.3 | 2.1 | 2.3 |
| Cost of Revenues | — | — | — | 0.0 | 0.2 | 1.2 | 1.3 |
| Gross Profit | — | — | — | 0.0 | 0.2 | 0.9 | 1.0 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 44.8 | 42.0 | 48.0 | 41.6 | 36.3 | 26.5 | 15.0 |
| Operating Income | (63.5) | (59.4) | (64.1) | (58.4) | (51.7) | (33.9) | (17.1) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 4.7 | 3.0 | 2.6 | 3.6 | 1.0 | 0.2 | 0.0 |
| EBT, Incl. Unusual Items | — | — | — | — | (50.5) | (33.8) | (17.0) |
| Income Tax Expense | — | — | — | — | — | (0.3) | — |
| Net Income | |||||||
| Net Income | (57.3) | (56.0) | (61.0) | (53.5) | (50.5) | (33.5) | (17.0) |
| Per Share | |||||||
| Basic EPS | (0.89) | (1.27) | (2.04) | (1.88) | (1.91) | (2.46) | (3.44) |
| Diluted EPS | (0.89) | (1.27) | (2.04) | (1.88) | (1.91) | (2.46) | (3.44) |
| Basic Weighted Avg Shares | 64.7 | 44.0 | 30.0 | 28.4 | 26.4 | 13.6 | 5.0 |
| Diluted Weighted Avg Shares | 64.7 | 44.0 | 30.0 | 28.4 | 26.4 | 13.6 | 5.0 |
| Supplemental | |||||||
| EBITDA | — | (59.1) | (63.7) | (58.1) | — | — | — |
| EBIT | (63.5) | (59.4) | (64.1) | (58.4) | (51.7) | (33.9) | (17.1) |
| Effective Tax Rate | — | — | — | — | — | 0.9% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.